



Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Marcus Harbord,^{a,†,#} Rami Eliakim,^{b,#} Dominik Bettenworth,^c
Konstantinos Karmiris,^d Konstantinos Katsanos,^e Uri Kopylov,^f
Torsten Kucharzik,^g Tamás Molnár,^h Tim Raine,ⁱ Shaji Sebastian,^j
Helena Tavares de Sousa,^k Axel Dignass,^{l,†} Franck Carbonnel;^{m,†}
for the European Crohn's and Colitis Organisation [ECCO]

^aImperial College London, and Chelsea and Westminster Hospital, London, UK ^bDepartment of Gastroenterology and Hepatology, Chaim Sheba Medical Center, Tel Hashomer, Israel ^cDepartment of Medicine B, University Hospital Münster, Münster, Germany ^dDepartment of Gastroenterology, Venizeleio General Hospital, Heraklion, Crete, Greece ^eDepartment of Gastroenterology and Hepatology, University and Medical School of Ioannina, Ioannina, Greece ^fDepartment of Gastroenterology, Tel-Hashomer Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University, Israel ^gDepartment of Internal Medicine and Gastroenterology, Hospital Lüneburg, Lüneburg, Germany ^hFirst Department of Medicine, University of Szeged, Szeged, Hungary ⁱDepartment of Medicine, University of Cambridge, Cambridge, UK ^jIBD Unit, Hull & East Yorkshire NHS Trust, Hull, UK ^kGastroenterology Department, Algarve Hospital Center; Biomedical Sciences & Medicine Department, University of Algarve, Faro, Portugal ^lDepartment of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany ^mDepartment of Gastroenterology, CHU Bicêtre, Université Paris Sud, Paris, France

[†]These authors contributed equally to this paper.

[#]These authors acted as convenors of the Consensus.

doi:10.1093/ecco-jcc/jjx009

After publication, the authors of the third European evidence-based consensus on diagnosis and management of ulcerative colitis (part 2: current management) have been made aware of one error in referencing in section '11.2.2. Left-sided colitis'. The error has been corrected in the article and the revised paragraph reads as follows.

Oral beclomethasone dipropionate is non-inferior, but not better tolerated, than prednisone after 4 weeks' treatment.³² Oral non-MMX budesonide does not appear to be efficient in the treatment of UC.^{33,37} Two phase 3 randomised controlled trials (RCTs) (Core I and Core II)^{34,35} have compared oral budesonide MMX 9 mg/day with placebo in patients with mild to moderate left-sided and extensive UC. The 8-week combined clinical and endoscopic remission rates were 20.3% vs 3.2% ($P = 0.0018$); and endoscopic healing rates were 27.6% vs 17.1% ($P = 0.009$), for budesonide MMX

and placebo, respectively.³⁶ In the Core I trial, budesonide MMX was also compared with oral Asacol at a dose of 2.4 g/day, and no difference was found.³⁴ In the Core II trial, budesonide MMX was also compared with non-MMX budesonide, and no difference was found³⁵—although the study was not adequately powered to do so. Subgroup analysis of both trials demonstrated that the benefit of budesonide MMX is confined to left-sided disease and not extensive colitis.³⁶ A randomised trial has compared oral budesonide MMX with placebo in patients with mild to moderately active UC inadequately controlled with oral 5-ASA. Budesonide MMX 9 mg/day induced clinical, endoscopic, and histological remission at Week 8 more frequently than placebo,³⁸ providing evidence for an alternative therapy to escalating to conventional steroids. However, there has been no head-to-head comparative trial between budesonide MMX and conventional steroids.³⁹